Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

被引：22

作者：

Cortellini, Alessio ^{[1
,2
]}

Cannita, Katia ^{[3
]}

Tiseo, Marcello ^{[4
,5
]}

Cortinovis, Diego L. ^{[6
]}

Aerts, Joachim G. J., V ^{[7
]}

Baldessari, Cinzia ^{[8
]}

Giusti, Raffaele ^{[9
]}

Ferrara, Miriam G. ^{[10
,11
]}

D'Argento, Ettore ^{[10
]}

Grossi, Francesco ^{[12
]}

Guida, Annalisa ^{[13
]}

Berardi, Rossana ^{[14
]}

Morabito, Alessandro ^{[15
]}

Genova, Carlo ^{[16
]}

Antonuzzo, Lorenzo ^{[17
]}

Mazzoni, Francesca ^{[17
]}

De Toma, Alessandro ^{[18
]}

Signorelli, Diego ^{[18
,19
]}

Gelibter, Alain ^{[20
]}

Targato, Giada ^{[21
]}

Rastelli, Francesca ^{[22
]}

Chiari, Rita ^{[23
]}

Rocco, Danilo ^{[24
]}

Gori, Stefania ^{[25
]}

De Tursi, Michele ^{[26
]}

Mansueto, Giovanni ^{[27
]}

Zoratto, Federica ^{[28
]}

Filetti, Marco ^{[9
]}

Bracarda, Sergio ^{[29
]}

Citarella, Fabrizio ^{[30
]}

Russano, Marco ^{[30
]}

Cantini, Luca ^{[7
,14
]}

Nigro, Olga ^{[31
]}

Buti, Sebastiano ^{[5
]}

Minuti, Gabriele ^{[32
]}

Landi, Lorenza ^{[32
]}

Ricciardi, Serena ^{[33
]}

Migliorino, Maria R. ^{[33
]}

Natalizio, Salvatore ^{[34
]}

Simona, Carnio ^{[35
]}

De Filippis, Marco ^{[35
]}

Metro, Giulio ^{[36
]}

Adamo, Vincenzo ^{[37
]}

Russo, Alessandro ^{[37
]}

Spinelli, Gian P. ^{[38
]}

Di Maio, Massimo ^{[39
,40
]}

Banna, Giuseppe L. ^{[41
]}

Friedlaender, Alex ^{[42
]}

Addeo, Alfredo ^{[42
]}

Pinato, David J. ^{[2
,43
]}

机构：

[1] Univ LAquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Div Canc, London, England

[3] St Salvatore Hosp, Med Oncol, Laquila, Italy

[4] Univ Parma, Dept Med & Surg, Parma, Italy

[5] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[6] Osped San Gerardo, Med Oncol, Monza, Italy

[7] Erasmus MC, Dept Pulm Dis, Rotterdam, Netherlands

[8] AOU Policlin Modena, Dipartimeto Oncol Ematol, Modena, Italy

[9] St Andrea Hosp, Med Oncolgy, Rome, Italy

[10] Fdn Policlin Univ Gemelli, Comprehens Canc Ctr, IRCCS, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Romae, Lazio, Italy

[12] Fdn IRCCS CaGranda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy

[13] Azienda Osped Santa Maria, Dept Oncol, Terni, Italy

[14] Univ Politecn Marche, Osped Riuniti Ancona, Oncol Clin, Ancona, Italy

[15] Ist Nazl Tumori, IRCCS, Thorac Med Oncol, Fdn G Pascale, Naples, Italy

[16] Osped Policlin San Martino, Lung Canc Unit, IRCCS, Genoa, Italy

[17] Careggi Univ Hosp, Dept Oncol, Florence, Italy

[18] Ist Nazl Tumori, Dept Med Oncol, Fdn IRCCS, Milan, Italy

[19] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy

[20] Sapienza Univ Rome, Policlin Umberto I, Med Oncol B, Rome, Italy

[21] Univ Hosp Santa Maria Misericordia, Dept Oncol, Udine, Italy

[22] Med Oncol, Fermo Area Vasta 4, Fermo, Italy

[23] Osped Riuniti Padova Sud Madre Teresa Calcutta, Med Oncol, Monselice, Italy

[24] Monaldi Hosp, Pneumo Oncol Unit, Naples, Italy

[25] Osped Sacro Cuore Don Calabria, IRCCS, Oncol Unit, Negrar, VR, Italy

[26] Oral & Biotechnol Sci Univ G DAnnunzio, Dept Med, Chieti, Italy

[27] Spaziani Hosp, Med Oncol, Frosinone, Italy

[28] Santa Maria Goretti Hosp, Med Oncol, Latina, Italy

[29] Azienda Osped Santa Maria Terni, Struttura Complessa Oncol Med & Traslaz, Terni, Italy

[30] Campus Biomed Univ, Med Oncol, Rome, Italy

[31] ASST Sette Laghi, Med Oncol, Varese, Italy

[32] AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy

[33] St Camillo Forlanini Hosp, Pneumo Oncol Unit, Rome, Italy

[34] Univ Modena & Raggio Emilia, Dipartimento Oncol Ematol, Modena, Italy

[35] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, TO, Italy

[36] Azienda Osped Perugia, Dept Med Oncol, Santa Maria Misericordia Hosp, Perugia, Italy

[37] Univ Messina, AO Papardo & Dept Human Pathol, Med Oncol, Messina, Italy

[38] Univ Rome Sapienza, UOC Terr Oncol Aprilia, AUSL Latina, Aprilia, Italy

[39] Univ Turin, Dept Oncol, Turin, Italy

[40] AO Ordine Mauriziano, Med Oncol, Turin, Italy

[41] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England

[42] Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland

[43] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2021年 / 148卷

关键词：

Non-small cell lung cancer; Immunotherapy; PD-L1; Pembrolizumab; Performance status; Post-progression; Radiotherapy; Radiation therapy; CELL LUNG-CANCER; IMMUNE-CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; RESPONSE RATES; IMMUNOTHERAPY; RADIOTHERAPY; ASSOCIATION; ASSAYS;

D O I：

10.1016/j.ejca.2021.02.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression >50%. Methods: We evaluated post-progression treatment pathways in a large real-world cohort of metastatic NSCLC patients with PD-L1 expression > 50% treated with first-line pembrolizumab monotherapy. Results: Overall, 974 patients were included. With a median follow-up of 22.7 months (95%CI: 21.6-38.2), the median overall survival (OS) of the entire population was 15.8 months (95% CI: 13.5-17.5; 548 events). At the data cutoff, among the 678 patients who experienced disease progression, 379 (55.9%) had not received any further treatment, and 359 patients (52.9%) had died. Patients who did not receive post-progression therapies were older (p = 0.0011), with a worse ECOG-PS (p < 0.0001) and were on corticosteroids prior to pembrolizumab (p = 0.0024). At disease progression, 198 patients (29.2%) received a switched approach and 101 (14.9%) received pembrolizumab ByPD either alone (64 [9.4%]) or in combination with local ablative treatments (37 [5.5%]) (LATs). After a random-case control matching according to ECOG-PS, CNS metastases, bone metastases, and (previous) best response to pembrolizumab, patients receiving pembrolizumab ByPD plus LATs were confirmed to have a significantly longer post-progression OS compared to patients receiving pembrolizumab ByPD alone 13.9 months versus 7.8 months (p = 0.0179) 241 patients (35.5%) among the 678 who had experienced PD, received a second-line systemic treatment (regardless of previous treatment beyond PD). As compared to first-line treatment commencement, patients' features at the moment of second-line initiation showed a significantly higher proportion of patients aged under 70 years (p = 0.0244), with a poorer ECOG-PS (p < 0.0001) and having CNS (p = 0.0001), bone (p = 0.0266) and liver metastases (p = 0.0148). Conclusions: In the real-world scenario NSCLC patients with PD-L1 expression >50% treated with first-line single-agent pembrolizumab achieve worse outcomes as compared to the Keynote-024 trial. Poor post-progression outcomes are major determinants of the global results that should be considered when counselling patients for first-line treatment choices. (c) 2021 Elsevier Ltd. All rights reserved.

引用

页码：24 / 35

页数：12

共 50 条

[1] Re: Post-progression outcomes of NSCLC patients with PD-L1 expression ≥50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Sutcuoglu, Osman
ozdemir, Nuriye
Yazici, Ozan
EUROPEAN JOURNAL OF CANCER, 2021, 155 : 294 - 295
[2] Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
Rittberg, Rebekah
Leung, Bonnie
Shokoohi, Aria
Pender, Alexandra
Wong, Selina
Al-Hashami, Zamzam
Wang, Ying
Ho, Cheryl
CURRENT ONCOLOGY, 2023, 30 (06) : 5299 - 5308
[3] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Cortellini, Alessio
Tiseo, Marcello
Banna, Giuseppe L.
Cappuzzo, Federico
Aerts, Joachim G. J., V
Barbieri, Fausto
Giusti, Raffaele
Bria, Emilio
Cortinovis, Diego
Grossi, Francesco
Migliorino, Maria R.
Galetta, Domenico
Passiglia, Francesco
Santini, Daniele
Berardi, Rossana
Morabito, Alessandro
Genova, Carlo
Mazzoni, Francesca
Di Noia, Vincenzo
Signorelli, Diego
Tuzi, Alessandro
Gelibter, Alain
Marchetti, Paolo
Macerelli, Marianna
Rastelli, Francesca
Chiari, Rita
Rocco, Danilo
Gori, Stefania
De Tursi, Michele
Mansueto, Giovanni
Zoratto, Federica
Santoni, Matteo
Tudini, Marianna
Rijavec, Erika
Filetti, Marco
Catino, Annamaria
Pizzutilo, Pamela
Sala, Luca
Citarella, Fabrizio
Marco, Russano
Torniai, Mariangela
Cantini, Luca
Targato, Giada
Sforza, Vincenzo
Nigro, Olga
Ferrara, Miriam G.
D'Argento, Ettore
Buti, Sebastiano
Bordi, Paola
Antonuzzo, Lorenzo
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (11) : 2209 - 2221
[4] Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Piedra, A.
Recio, S. Martinez
Gonzalez, A. Hernandez
Bueno, M. T. Moran
Arriola, E.
Recuero-Borau, J.
Dols, M. Cobo
Gonzalez, P. Cordeiro
Martinez, J. Mosquera
Garcia-Campelo, M. R.
Blanco, A. Calles
Alvarez, R. M.
Garcia, M. Zapata
Casado, M. D. Isla
Perez, A. Callejo
Gomez, P. Iranzo
Joaquin, A. Barba
Sullivan, I. G.
Felip, E.
Majem, M.
ANNALS OF ONCOLOGY, 2023, 34
[5] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Alessio Cortellini
Marcello Tiseo
Giuseppe L. Banna
Federico Cappuzzo
Joachim G. J. V. Aerts
Fausto Barbieri
Raffaele Giusti
Emilio Bria
Diego Cortinovis
Francesco Grossi
Maria R. Migliorino
Domenico Galetta
Francesco Passiglia
Daniele Santini
Rossana Berardi
Alessandro Morabito
Carlo Genova
Francesca Mazzoni
Vincenzo Di Noia
Diego Signorelli
Alessandro Tuzi
Alain Gelibter
Paolo Marchetti
Marianna Macerelli
Francesca Rastelli
Rita Chiari
Danilo Rocco
Stefania Gori
Michele De Tursi
Giovanni Mansueto
Federica Zoratto
Matteo Santoni
Marianna Tudini
Erika Rijavec
Marco Filetti
Annamaria Catino
Pamela Pizzutilo
Luca Sala
Fabrizio Citarella
Russano Marco
Mariangela Torniai
Luca Cantini
Giada Targato
Vincenzo Sforza
Olga Nigro
Miriam G. Ferrara
Ettore D’Argento
Sebastiano Buti
Paola Bordi
Lorenzo Antonuzzo
Cancer Immunology, Immunotherapy, 2020, 69 : 2209 - 2221
[6] First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
Amrane, K.
Geier, M.
Corre, R.
Leveiller, G.
Florence, G.
Lamy, R.
Bizec, J. L.
Goarant, E.
Robinet, G.
Ulrike, S.
Quere, G.
Bernier, C.
Descourt, R.
ANNALS OF ONCOLOGY, 2019, 30
[7] Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001)
Kitamura, Yasuo
Mizugaki, Hidenori
Ikezawa, Yasuyuki
Morita, Ryo
Tateishi, Kazunari
Yokoo, Keiki
Sumi, Toshiyuki
Kikuchi, Hajime
Nakamura, Atsushi
Kobayashi, Maki
Aso, Mari
Kimura, Nozomu
Yoshiike, Fumiaki
Furuta, Megumi
Tanaka, Hisashi
Sekikawa, Motoki
Hachiya, Tsutomu
Nakamura, Keiichi
Oizumi, Satoshi
ANNALS OF ONCOLOGY, 2022, 33 : S524 - S524
[8] Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: RealWorld Data from a European Cohort
Metro, G.
Signorelli, D.
Rey-Cobo, J.
Banini, M.
Economopoulou, P.
Lo Russo, G.
Baxevanos, P.
Roila, F.
De Toma, A.
Banna, G.
Christopoulou, A.
Jimenez, B.
Collazo-Lorduy, A.
Linardou, H.
Calles Blanco, A.
Galetta, D.
Addeo, A.
Camerini, A.
Kosmidis, P.
Garassino, M.
Mountzios, G.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S589
[9] Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
Cortellini, Alessio
Friedlaender, Alex
Banna, Giuseppe L.
Porzio, Giampiero
Bersanelli, Melissa
Cappuzzo, Federico
Aerts, Joachim G. J., V
Giusti, Raffaele
Bria, Emilio
Cortinovis, Diego
Grossi, Francesco
Migliorino, Maria R.
Galetta, Domenico
Passiglia, Francesco
Berardi, Rossana
Mazzoni, Francesca
Di Noia, Vincenzo
Signorelli, Diego
Tuzi, Alessandro
Gelibter, Alain
Marchetti, Paolo
Macerelli, Marianna
Rastelli, Francesca
Chiari, Rita
Rocco, Danilo
Inno, Alessandro
Di Marino, Pietro
Mansueto, Giovanni
Zoratto, Federica
Santoni, Matteo
Tudini, Marianna
Ghidini, Michele
Filetti, Marco
Catino, Annamaria
Pizzutilo, Pamela
Sala, Luca
Occhipinti, Mario Alberto
Citarella, Fabrizio
Marco, Russano
Torniai, Mariangela
Cantini, Luca
Follador, Alessandro
Sforza, Vincenzo
Nigro, Olga
Ferrara, Miriam G.
D'Argento, Ettore
Leonetti, Alessandro
Pettoruti, Linda
Antonuzzo, Lorenzo
Scodes, Simona
CLINICAL LUNG CANCER, 2020, 21 (06) : 498 - +
[10] 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
Velcheti, Vamsidhar
Rai, Pragya
Kao, Yu-Han
Chirovsky, Diana
Nunes, Ana Tablante
Liu, Stephen, V
CLINICAL LUNG CANCER, 2024, 25 (06)

← 1 2 3 4 5 →

Post-progression outcomes of NSCLC patients with PD-L1 expression &gt; 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study